Loading...
Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease
The advent of immune checkpoint inhibitors (ICIs) for cancer therapy has heralded increasing frequency of immune-related adverse events including endocrinopathies, hepatitis, colitis and rarely myocarditis and myasthenia gravis (MG). The heterogeneity in clinical presentations regardless of organ-sp...
Na minha lista:
| Udgivet i: | BMJ Case Rep |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7228148/ https://ncbi.nlm.nih.gov/pubmed/32404371 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2019-232920 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|